Connecticut Adds Eight New Qualifying Medical Cannabis Conditions

Connecticut officials have added eight new conditions to the list that qualifies an individual to become a legal consumer of medical cannabis.

On Tuesday Connecticut’s Department of Consumer Protection announced an expansion of the state’s medical cannabis program which will significantly increase the number of people eligible to take part in it.  The move – which is expected to be made final by the Secretary of State’s office within a week – takes the state’s already expansive list of qualifying conditions and adds eight more (six for those 18+ and two for minors).

The Department added the following conditions for those 18 and older:

  • Spasticity — continuously contracting muscles — or neuropathic pain associated with fibromyalgia
  • Severe rheumatoid arthritis
  • Post herpetic neuralgia — a complication of shingles caused by chickenpox
  • Hydrocephalus, or water on the brain, with intractable headache
  • Intractable headache syndromes
  • Neuropathic facial pain

 

For those under 18, the following conditions were added:

  • Muscular dystrophy
  • Osteogenesis imperfecta

 

“Now that these regulations have been accepted, more patients with severe medical conditions will have access to medical marijuana as a treatment option,” said Consumer Protection Commissioner Michelle H. Seagull in a recent statement. “I want to thank our Board of Physicians and the committee for their thoughtful consideration of these conditions. I continue to be proud of the careful way that our program has expanded, and its commitment to a true medical model.”

Below is a list of the other conditions that qualify an individual to become a medical cannabis patient:

  • Cancer
  • Glaucoma
  • Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity
  • Epilepsy
  • Cachexia
  • Wasting Syndrome
  • Crohn’s Disease
  • Post-Traumatic Stress Disorder
  • Sickle Cell Disease
  • Post Laminectomy Syndrome with Chronic Radiculopathy
  • Severe Psoriasis and Psoriatic Arthritis
  • Amyotrophic Lateral Sclerosis
  • Ulcerative Colitis
  • Complex Regional Pain Syndrome
  • Cerebral Palsy
  • Cystic Fibrosis
  • Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity
  • Terminal Illness Requiring End-Of-Life Care
  • Uncontrolled Intractable Seizure Disorder
  • Spasticity or Neuropathic Pain Associated with Fibromyalgia
  • Severe Rheumatoid Arthritis
  • Post Herpetic Neuralgia
  • Hydrocephalus with Intractable Headache
  • Intractable Headache Syndromes
  • Neuropathic Facial Pain

For Patients Under 18, medical cannabis conditions Include:

  • Cerebral Palsy
  • Cystic Fibrosis
  • Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity
  • Severe Epilepsy
  • Terminal Illness Requiring End-Of-Life Care
  • Uncontrolled Intractable Seizure Disorder
  • Muscular Dystrophy
  • Osteogenesis Imperfecta

Leave a Reply

Your email address will not be published.